Accendra Health price to free cash flow ACH

Market value divided by free cash flow over the last twelve months, since 2011.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 193×; Feb 2025
10-year median: 8.7×
10-year range: 1.5× to 300×
Peer median: 10.4×

Accendra Health's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Feb 2025, at 193×.

On the days it had one over the last ten years, its median was 8.7×, from 1.5× in May 2020 to 300× in Jan 2025.

Price to free cash flow over time

median 8.7×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	193×	125×	300×
2024	260×	2.5×	280×
2023	2.8×	2.4×	10.4×
2022	9.0×	6.1×	42.5×
2021	36.6×	7.3×	37.0×
2020	7.6×	1.5×	8.5×
2019	3.6×	2.9×	8.7×
2018	3.0×	2.9×	78.5×
2017	67.4×	11.4×	69.7×
2016	11.5×	9.2×	45.9×
2015	24.2×	15.4×	106×
2014	104×	11.8×	104×
2013	12.6×	8.0×	13.2×
2012	9.2×	7.9×	62.1×
2011	55.4×	16.4×	61.6×

Against its peers

Companies in Healthcare nearest Accendra Health's size, closest first, today.

Company	Price to free cash flow
ACHAccendra Health	n/m
NEPHNephros	n/m
ATNMActinium Pharmaceuticals	n/m
APTAlpha Pro Tech	9.7×
SPROSpero Therapeutics	n/m
LFVNLifevantage	11.0×
ICCCImmucell	22.1×
KEQUKewaunee Scientific	8.7×
Peer median	10.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Accendra Health

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.